Actively Recruiting
Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study
Led by University Hospital, Angers · Updated on 2025-12-08
55
Participants Needed
1
Research Sites
317 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Septic shock is defined as a subset of sepsis with severe metabolism alterations, leading to organ failure. Septic shock is associated with a high mortality, around 40% according to the SEPSIS 3 definition. Metabolic alterations are responsible for lactic acidosis, and results in mitochondrial dysfunction. This study aims at evaluate the impact of exogenous metabolites on restoring mitochondrial function in septic shock patients with lactate acidosis. Mitochondrial metabolism (quantitative analysis, mitochondrial function) in intact Peripheral Blood Mononuclear Cells (PBMC) will be isolate and analyse from patients at the early phase of septic shock (admission), at day 2 and 4. Participant's medical history will be recorded: renal and liver metabolism, severity scores and outcomes and the need for supportive care in the intensive care unit (ICU) until 28 days after admission. Furthermore, the investigators will evaluate wether selected metabolites added to the cell culture medium may improve mitochondrial metabolism.
CONDITIONS
Official Title
Impact of Metabolite Supplementation to Restore Mitochondrial Dysfunction During Septic Shock: a Preclinical Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All patients aged 18 or more
- Patients with septic shock according to SEPSIS 3 definition (sepsis with low blood pressure needing vasopressors to keep mean arterial pressure > 65 mmHg and serum lactate > 2 mmol/L despite fluids)
- Admitted to the ICU of Angers University Hospital
You will not qualify if you...
- Patients younger than 18 years
- Patients under legal protection measures
- Patients or families who refuse participation
- Patients with preexisting mitochondrial disease
- Patients with aplasia
- Pregnant or parturient women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU
Angers, Maine et Loire, France, 49933
Actively Recruiting
Research Team
J
Julien DEMISELLE, MD
CONTACT
P
Pierre ASFAR, MD PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here